Introduction
The liver is the most frequent site of metastasis from colorectal cancer (1, 2) . Surgical resection is considered the only curative therapy for colorectal liver metastasis (CLM) (3, 4) ; however, only 25% of patients are eligible for hepatic resection with a curative intent (5, 6) . Recently, new anticancer drugs including oxaliplatin have improved treatment results for colorectal cancer and enabled patients with initially unresectable CLM to undergo hepatic resections after neoadjuvant chemotherapy (7) . Despite its benefits, however, preoperative oxaliplatin-based chemotherapy for CLM induces damage in the nontumorous liver parenchyma, known as sinusoidal obstruction syndrome (SOS) (8, 9) , which is characterized by sinusoidal dilatation, endothelial damage in the central vein, and coagulative necrosis of hepatocytes (9) . In patients with CLM, SOS contributes to postoperative morbidity after hepatectomy (10) ; therefore, a strategy to control SOS needs to be developed.
In a rat model of monocrotaline (MCT)-induced SOS, matrix metalloproteinase-9 (MMP-9) was described as a key mediator in the development of SOS (11, 12) . In fact, MMP inhibitors have been shown to block the progression of SOS in the animal model, but the detailed mechanism has not been elucidated (12) . We previously reported that sorafenib, a multikinase inhibitor, also attenuated MCT-induced SOS via MMP-9 suppression (13).
However, a phase IIb study did not show a benefit in progression-free survival with the addition of sorafenib to oxaliplatin-based chemotherapy (14) . Therefore, further clinical trials of sorafenib for colorectal cancer have not been conducted, indicating that future application of sorafenib for CLM is unlikely.
Regorafenib is a novel oral multikinase inhibitor that targets various protein kinases such as vascular endothelial growth factor receptors (VEGFR) 1/2/3, tyrosine kinase with immunoglobulin and epidermal growth factor homology domain 2 (TIE-2), platelet-derived growth factor receptor-beta (PDGFR-beta), c-kit, ret, raf-1, and B-RAF (15) . An international phase 3 trial (CORRECT) demonstrated a statistically significant improvement in overall survival and progression-free survival when regorafenib was administered to patients with metastatic colorectal cancer that progressed after all other approved standard therapies (16) . On the basis of this trial, regorafenib was approved for metastatic colorectal cancer in several countries, including the US, Canada, Europe, and Japan. Furthermore, a phase 1b study of combined therapy with regorafenib and oxaliplatin-based chemotherapy has been reported (17) . Wilhelm et al. showed that regorafenib inhibited the phosphorylation of extracellular signal-regulated kinase (ERK), which is reported to be necessary for MMP-9 activation (15, 18) . Thus, regorafenib also has the potential to attenuate SOS, similarly to sorafenib. However, it would be premature to conclude that regorafenib has a protective effect against SOS in the way sorafenib does, because the structure of regorafenib differs from that of sorafenib, resulting in a different biochemical profile from sorafenib (15) .
The purpose of the present study was to examine the impact of regorafenib on SOS in a rat model and to clarify whether regorafenib improves mortality after hepatic resection.
Materials and Methods

Reagents
Monocrotaline (MCT) was purchased from Sigma-Aldrich (St. Louis, MO, USA). A solution of MCT was prepared at 10 mg/mL, as previously reported (19) . Regorafenib, a multikinase inhibitor, was prepared as a solution in polypropylene glycol/PEG400/Pluronic F68 (42.5/42.5/15 + 20% Aqua). The regorafenib compound (kindly provided by Bayer HealthCare Pharmaceuticals Inc. [Whippany, NJ, USA]) was stored at room temperature in the dark (15) . Polypropylene glycol and PEG400 were purchased from Wako Pure Chemical Industries (Osaka, Japan). Pluronic F68 was purchased from Sigma-Aldrich.
Animals
We used 7-9-week-old male Sprague-Dawley rats (SLC, Shizuoka, Japan) weighing 250-350 g. The animals had free access to food and water. All experiments were conducted in accordance with the guidelines for the care and use of laboratory animals of the animal research committee of Kyoto University. The animals received humane care in accordance with the NIH Guidelines for the Care and Use of Laboratory Animals.
Experimental protocol
MCT-treated rats were used as the experimental model of SOS (13, 20, 21) . Rats were fasted for 12 h before oral administration of MCT, but had free access to water. MCT (90 mg/kg) was administered by gavage, after which the rats were allowed to consume food and water ad libitum. To evaluate the efficacy of regorafenib on SOS, the rats were divided into 2 groups (n = 20 in each group) according to treatment with regorafenib (6 mg/kg) or vehicle, by oral gavage, 12 h and 36 h before MCT treatment. The administered volume of vehicle was the same as the volume of regorafenib. Subsequently, some of the rats were sacrificed 48 h after MCT administration and samples of blood and liver tissue were taken, because the histopathological changes at 48 h after MCT treatment in rats have been found to be most similar to those in human SOS (21) . Some animals were sacrificed and samples were collected at two different time points. Partial hepatectomy (30%, left lateral lobectomy) was performed in SOS rats treated with regorafenib or vehicle (another 15 rats in each group) 48 h after MCT administration. These animals were monitored for 7 days to examine survival after surgery, while other animals were sacrificed at 24 h after surgery.
Histopathology
Liver tissue samples were fixed in 4% paraformaldehyde (PFA), embedded in paraffin wax, and cut into 4 µm sections. Histologic assessment of SOS was performed using hematoxylin and eosin (H&E) staining by a single pathologist (A.M-H.) in a blinded manner. To quantify the degree of SOS, histological changes were scored, as previously reported (20, 21) . Sinusoidal hemorrhage, endothelial damage in the central vein, and coagulative necrosis of hepatocytes were graded on a 4-point scale: 0, absent; 1, mild; 2, moderate; and 3, severe. The total SOS score was calculated as the sum of the individual scores.
Serum biochemistry
Assessment of biologic data at 48 h after MCT treatment included serum aspartate transaminase (AST), alanine transaminase (ALT), and albumin (Alb) level measurements.
Immunohistochemistry
Endothelial cells were stained using rat endothelial cell antigen-1 (RECA-1:
MCA-970R; AbD Serotec, Oxford, UK), as previously described (21) . Tissues were directly embedded in optimal cutting temperature compound (Sakura, Tokyo, Japan).
Sections were cut at a 6-µm thickness and fixed with 4% PFA for 10 min at room temperature. Sections were blocked and then incubated with the primary antibody RECA-1 at a 1:500 dilution for 1 h at 4°C. Subsequently, the sections were incubated with labeled polymer using an EnVision + System HRP kit (Dako, Tokyo, Japan), at room temperature for 1 h. The sections were examined after incubation using the Liquid DAB Substrate-Chromogen System (Dako). Ten high-power fields (200×) were randomly selected for calculating the staining area of the endothelial cells. The staining area was quantified using Image J (National Institutes of Health).
For the terminal deoxynucleotidyl transferase-mediated dUTP nick end-loading (TUNEL) assay, we used a commercial kit (In situ Apoptosis Detection Kit; Takara Bio Inc., Shiga, Japan) according to the manufacturer's instructions. TUNEL stained areas were examined in different locations of the tissue section in 10 low-power fields (100×) using Image J.
Immunohistochemistry for cleaved caspase-3 was performed using standard protocols with a primary antibody that recognizes cleaved caspase-3 (Asp175) (#9102, Cell Signaling Technology, Inc. (CST), Danvers, MA, USA). Briefly, the sections were deparaffinized and quenched with hydrogen peroxide, and antigen retrieval was performed using sodium citrate buffer at a sub-boiling temperature for 10 minutes. Subsequently, the sections were incubated with primary antibodies at a 1:400 dilution overnight at 4°C, followed by incubation with an EnVision + System HRP kit (Dako) for 30 minutes at room temperature.
Signals were detected using the Liquid DAB Substrate-Chromogen System (Dako), and the sections were counterstained with hematoxylin.
Electron microscopy
Rats were first perfused, through the abdominal aorta, with phosphate buffered saline (PBS) and then with a fixative containing 2% glutaraldehyde and 4% PFA. The livers were cut into small pieces (approximately 1 mm 3 ) for transmission electron microscopy (TEM) and into larger pieces (5 mm 3 ) for scanning electron microscopy (SEM). The samples were fixed in 2% glutaraldehyde and 4% PFA at 4°C. Thin sections were stained with saturated uranyl acetate and lead citrate and were observed using a Hitachi H-7650 electron microscope for TEM. Samples were ion-sputter-coated and observed with a Hitachi S-4700 
MMP gelatin zymography
Total protein from the whole liver was purified and 10 µg of protein was used in each sample. Gelatin zymography was performed using a Gelatin Zymo electrophoresis kit (Cosmo Bio Co., Tokyo, Japan), according to the manufacturer instructions.
Western blot analysis
Frozen liver tissues were homogenized in lysis buffer containing 10 mmol/L Tris-HCl (pH 7.4), 150 mmol/L NaCl, 1% Nonidet P-40, protease inhibitor, and phosphatase inhibitor. Equal amounts of total protein were subjected to 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis, separated by electrophoresis, and transferred onto Immobilon-NC transfer membranes (Millipore Corporation, Billerica, MA, USA). After blocking with 5% skim milk in TBS-Tween for 1 h, the membranes were incubated with a primary antibody recognizing ERK (#9102, CST), phosphorylated-specific ERK (#9101, CST) or GAPDH (sc-25778, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) at a 1:1000 dilution overnight at 4°C. After treating the membranes with the primary antibodies, a peroxidase-conjugated goat anti-rabbit IgG (sc-2004, Santa Cruz) secondary antibody was used at a 1:2000 dilution for 1 h at room temperature. Subsequently, bands were detected using ECL reagent (GE Healthcare UK Ltd., Buckinghamshire, UK) and the Ez-Capture II camera (ATTO, Tokyo, Japan). Results were analyzed using Image J.
Statistical analysis
Data were analyzed using JMP 10.0 (SAS Institute, Cary, NC, USA). The Student t-test was used for comparison between groups. Survival after hepatectomy was analyzed using the Kaplan-Meier method, and differences were evaluated using the log-rank test. P values of <0.05 were considered statistically significant. Data are expressed as means ± SD.
Results
Regorafenib attenuates MCT-induced SOS
In the animals treated with MCT plus vehicle, macroscopic examination at 48 h after MCT administration showed that the liver surface was irregular, that it had turned dark red in color, and that bloody ascites had accumulated. These findings were less pronounced in the regorafenib group. Microscopically, the liver tissue of the animals in the vehicle group displayed the typical features of SOS, with severe sinusoidal hemorrhage, sinusoidal dilatation, coagulative necrosis of hepatocytes, and endothelial damage in the central vein ( Fig. 1D and E) . Liver sections from the regorafenib group showed a mild degree of SOS, with slight sinusoidal hemorrhage and dilatation compared with the vehicle group ( Fig. 1G and H). The SOS score in the regorafenib group was significantly lower than that in the vehicle group (Table 1) .
With regard to serum biochemistry evaluations at 48 h after MCT administration, AST and ALT levels were significantly lower in the regorafenib group than in the vehicle group.
Furthermore, the Alb level was markedly reduced in the vehicle group compared to the regorafenib group (Table 1) . These results suggest that regorafenib attenuated SOS.
Regorafenib reduced necrosis in SOS liver
Hepatocytes undergoing necrosis were detected according to morphologic criteria (vacuolization, loss of structure, karyolysis) with H&E staining. Moreover, to assess the mode of cell death, the sections were then stained using the TUNEL assay and an antibody against cleaved caspase-3.
In the TUNEL assay, TUNEL-positive cells were overlapped with the necrotic areas, as identified by H&E staining (Fig. 1F and I) . However, based on morphological criteria, these cells were not apoptotic. Most TUNEL-positive cells showed nuclear and, especially, cytoplasmic staining, which are both typically observed in cells undergoing oncotic necrosis (22, 23) . Immunohistochemistry for cleaved caspase-3 revealed that there were only a few positive cells in the necrotic areas, which were detected by H&E staining and TUNEL staining (Fig. A.1 ). As caspase-3 activation is one of the most typical characteristics observed with apoptosis (23), these results indicated that necrosis was the main constituent of SOS-induced cell death. Thus, we defined the TUNEL-positive area as the area of necrosis, which was significantly decreased in the regorafenib group compared to the vehicle group (1.40% ± 0.21% vs. 9.62% ± 0.99%, p < 0.05; Fig. 1J ).
Regorafenib improves survival after 30% partial hepatectomy in SOS rats
To evaluate the effect of regorafenib on remnant liver function after partial hepatectomy in rats with SOS, partial hepatectomy (30%) was performed in SOS rats treated with regorafenib or vehicle. Kaplan-Meier curves are shown in Fig. 2A . The survival rate at 7 days after surgery was significantly better in the regorafenib group than in the vehicle group (26.7% vs. 6.7%, p < 0.05), indicating that regorafenib improved survival after 30% hepatectomy in rats with SOS.
To explore the cause of death after hepatectomy, histopathological examinations were performed in both groups at 24 h after hepatectomy (i.e., 72 h after MCT administration with hepatectomy). The necrotic areas were further expanded in the vehicle group (Fig. 2B) but not in the regorafenib group (Fig. 2C) . When a hepatic resection was not performed, the necrotic areas were absorbed in both groups at the same time point (Fig. 2D and E) , which reflected the stage of recovery from liver injury. These results suggested that the hepatic resection promoted the further development of SOS, but that regorafenib may diminish the extent of SOS after hepatectomy, resulting in an improvement of post-operative survival.
Regorafenib diminished the loss of SECs due to SOS
To quantitatively assess the impact of regorafenib on SECs, RECA-1 immunohistochemistry was performed and areas with relative RECA-1 positivity were examined (Fig. 3) . Compared with untreated rats, areas with relative RECA-1 positivity in the vehicle group significantly decreased with time from 6 h to 48 h after MCT administration. In contrast, areas with RECA-1 positivity were significantly larger in the regorafenib group than in the vehicle group both at 6 h and at 48 h. These results indicated that regorafenib diminished the loss of SECs during the development of SOS.
Regorafenib mitigates the SOS-induced morphological damage of SECs as observed on electron microscopy
To evaluate the morphological changes of SECs in the SOS liver, electron microscopy was performed. SEM showed severe sinusoidal injury in the liver sections of vehicle-treated rats at 48 h after MCT administration: SECs were completely detached and lost, hepatocytes were directly exposed to sinusoids, and hepatic sinusoids were occupied by red blood cells (Fig. 4A ). In the regorafenib group, although SEC injury with enlarged fenestrae was observed, SECs were preserved on the sinusoidal walls (Fig. 4B ). On TEM, SECs were completely detached from the sinusoidal walls and blood cells had accumulated between SECs and hepatocytes in vehicle-treated rats (Fig. 4C) . In contrast, in regorafenib-treated rats, part of the space of Disse was dilated, but SECs were relatively maintained on parenchymal cells without sinusoidal congestion (Fig. 4D) . These results indicated that regorafenib suppressed the morphological injury of SECs during the development of SOS.
Regorafenib decreases MMP-9 activity and ERK phosphorylation in SOS livers
To assess the effect of regorafenib on MMP-9 activity in SOS livers, gelatin zymography was performed. It demonstrated that relative MMP-9 activity at 48 h after MCT treatment in the vehicle group was increased about 6.5 times from that in normal liver, whereas that in the regorafenib group was about 1.7 times higher than normal. Hence, the activity in the regorafenib group at 48 h after MCT administration was significantly lower than that in the vehicle group (Fig. 5 A and B) .
Phosphorylation of ERK was also examined, because it was reported to be necessary for MMP-9 activation (18). According to Western blot analyses of phosphorylated-ERK and total ERK, the relative ratio of p-ERK protein expression to total ERK protein expression in the vehicle group at 6 h after MCT administration was increased about twofold compared to that of the normal rats (p<0.001). In contrast, the relative ratio of p-ERK/ERK in the regorafenib group was significantly attenuated compared with the vehicle group (1.21 ± 0.32 vs. 2.09 ± 0.44, p<0.01) and was equivalent to that of the normal rats ( Fig. 5 C and D) . These results suggested that regorafenib decreased MMP-9 activation and ERK phosphorylation in SOS liver.
Discussion
SOS is a form of drug-induced liver injury caused by ingestion of pyrrolidine alkaloids
and cytotoxic drugs such as azathioprine, cyclophosphamide, busulfan, and dacarbazine. It was initially considered a complication of high-dose chemotherapy used as conditioning regimens for bone marrow transplantation for hematologic malignancies (24) and is now a well-known contributor to morbidity and mortality after stem cell transplantation (25) . For patients with CLM, Rubbia-Brandt et al. first described SOS as a significant hepatic adverse effect of oxaliplatin-based chemotherapy (9) . In human studies, although various Associated with recent developments in chemotherapy for colorectal cancer, newly developed drugs including oxaliplatin produce high response rates in patients with CLM, ranging from 43% to 60% (31, 32, 33) , compared with the rates of traditional drugs, which range from 18% to 30% (34, 35) . A recent study reported that 22.5% of patients with initially unresectable CLM underwent curative resection following neoadjuvant chemotherapy and that their overall survival was comparable to that of patients with resectable CLM (36). The incidence of hepatic resection following neoadjuvant chemotherapy in patients with CLM may therefore increase in the future. In patients with CLM, SOS is detected in 51-64% of patients after oxaliplatin-based chemotherapy (9, 37, 38) and is a serious concern because of its adverse effects. Vreuls et al. reported that a higher grade of SOS was associated with a lower tumor response to neoadjuvant oxaliplatin treatment (38) . Nakano et al. reported that SOS increased morbidity after major hepatectomy in patients with CLM (10). Tamandl 
